Central Trust Company’s Supernus Pharmaceuticals SUPN Stock Holding History

Central Trust Company’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-228	Closed	-$14K	–	1290
2018 Q2	$14K	Sell	228 -40	-15%	-$2.07K	﹤0.01%	901
2018 Q1	$12K	Sell	268 -500	-65%	-$20.9K	﹤0.01%	942
2017 Q4	$31K	Hold	768	–	–	﹤0.01%	785
2017 Q3	$31K	Sell	768 -936	-55%	-$40.5K	﹤0.01%	766
2017 Q2	$73K	Sell	1,704 -151	-8%	-$5.37K	﹤0.01%	611
2017 Q1	$58K	Hold	1,855	–	–	﹤0.01%	681
2016 Q4	$47K	Sell	1,855 -329	-15%	-$7.35K	﹤0.01%	719
2016 Q3	$54K	Buy	2,184 +1,059	+94%	+$24K	﹤0.01%	659
2016 Q2	$23K	Buy	+1,125	New	+$20K	﹤0.01%	841

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Central Trust Company's SUPN Position: Q3 2018 in Review

Central Trust Company sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 228 shares — an estimated $14K sold.

Central Trust Company first reported a position in SUPN in Q2 2016 and held it in 9 quarters. The position peaked at $73K in Q2 2017. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

Central Trust Company reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Central Trust Company sold 228 Supernus Pharmaceuticals shares in Q3 2018, an estimated $14K.
Central Trust Company first reported a position in Supernus Pharmaceuticals in Q2 2016 and held it in 9 quarters.
Central Trust Company's Supernus Pharmaceuticals position peaked at $73K in Q2 2017.
288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on Central Trust Company's 13F filing for Q3 2018, filed 4 Oct 2018.